JSPR · Jasper Therapeutics, Inc.
$0.70
+0.00 (+0.07%)
At close · Aug 28
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Accordingly, the Company has concluded that substantial doubt exists about its ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$23.28M
Shares
33.27M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Ronald Martell | Former Chief Executive Officer and President | $2,494,099 |
| Edwin Tucker | Former Chief Medical Officer | $1,537,032 |
| Jeet Mahal | Chief Executive Officer and President; Former Chief Operating Officer | $1,289,599 |
| Herb Cross | Chief Financial Officer and Corporate Secretary | $1,283,474 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Ronald Martell | President and Chief Executive Officer | $3,215,003 |
| Edwin Tucker | Chief Medical Officer | $1,400,620 |
| Jeet Mahal | Chief Operating Officer | $1,278,131 |
| Herb Cross | Chief Financial Officer and Corporate Secretary | $1,270,940 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Ronald Martell | President and Chief Executive Officer | $3,369,990 |
| Jeet Mahal | Chief Operating Officer | $1,184,707 |
| Edwin Tucker | Chief Medical Officer | $977,726 |
| Herb Cross | Chief Financial Officer and Corporate Secretary | $643,122 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Ronald Martell | President and Chief Executive Officer | $5,640,190 |
| Jeet Mahal | Chief Operating Officer | $1,107,520 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| William Lis | Former Executive Chairman, Chief Executive Officer and President | $679,289 |
| Kevin N. Heller | Executive Vice President, Research and Development | $617,987 |
| Jeet Mahal | Chief Financial Officer, Chief Operating Officer and Corporate Secretary | $461,121 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| William Lis | Former Executive Chairman, Chief Executive Officer and President | $1,571,061 |
| Kevin N. Heller | Executive Vice President, Research and Development | $1,212,858 |
| Jeet Mahal | Chief Financial Officer, Chief Operating Officer and Corporate Secretary | $719,959 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Matthew Ros | Chief Operating Officer | Appointed | 2026-07-17 |
| Patrick Crutcher | Class I director | Appointed | 2026-07-17 |
| Scott Brun, M.D. | Director | Resigned | 2026-07-17 |
| Vishal Kapoor | Director | Resigned | 2026-07-17 |
| Christian Nolet | Board | Resigned | 2026-05-21 |
| Jeet Mahal | Chief Executive Officer and President | Appointed | 2026-01-07 |
| Thomas G. Wiggans | Executive Chair | Appointed | 2026-01-07 |
| Jeet Mahal | Class III director | Appointed | 2026-01-07 |
| Ron Martell | Director | Resigned | 2026-01-07 |
| Ron Martell | Chief Executive Officer and President | Terminated | 2026-01-07 |
| Dr. Edwin Tucker, M.D. | Chief Medical Officer | Terminated | 2025-07-09 |
| Svetlana Lucas, Ph.D. | Class III director | Appointed | 2024-06-20 |
| Anna French, D.Phil. | Director | Resigned | 2024-06-20 |
| Christian W. Nolet | Class III director | Appointed | 2024-06-12 |
| Ronald Martell | Class III director | Appointed | 2024-06-12 |
| William Lis | Chairperson of the Board | Resigned | 2023-11-01 |
| William Lis | Board | Resigned | 2023-11-01 |
| Thomas G. Wiggans | Chairperson of the Board | Appointed | 2023-11-01 |
| Thomas G. Wiggans | Class II director | Appointed | 2023-11-01 |
| Herb Cross | principal accounting officer | Appointed | 2023-09-25 |
| Herb Cross | Chief Financial Officer and Corporate Secretary | Appointed | 2023-09-25 |
| Lawrence Klein | member of the Board | Resigned | 2023-06-20 |
| Scott Brun, M.D. | Class I director | Appointed | 2023-06-20 |
| Judith Shizuru, M.D., Ph.D. | Class II director | Appointed | 2023-06-08 |
| Anna French, D. Phil. | Class II director | Appointed | 2023-06-08 |
Key facts
CIK
1788028
CUSIP
471871202
13F (30d)
52 filings
51 filers
Visit website
Investor relations